STOCK TITAN

Corvus Pharmaceuticals, Inc. - $CRVS STOCK NEWS

Welcome to our dedicated page for Corvus Pharmaceuticals news (Ticker: $CRVS), a resource for investors and traders seeking the latest updates and insights on Corvus Pharmaceuticals stock.

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is a pioneering clinical-stage biopharmaceutical company focused on the development of novel immunotherapies to treat a broad spectrum of cancers and immune diseases. The company's core innovation is the selective inhibition of interleukin-2-inducible T cell kinase (ITK), which plays a crucial role in T cell and natural killer (NK) cell immune functions. Corvus' lead investigational product, soquelitinib (formerly CPI-818), has shown promise in optimizing T cell differentiation and enhancing immune responses against tumors, as well as in the management of autoimmune diseases.

Corvus is advancing soquelitinib through a Phase 3 registrational trial for relapsed peripheral T cell lymphoma (PTCL), an aggressive and typically treatment-resistant form of non-Hodgkin’s lymphoma. The company’s focus on ITK inhibition offers a new therapeutic approach, given the lack of FDA-approved treatments for relapsed PTCL. Soquelitinib has demonstrated the ability to prevent T cell exhaustion and promote the generation of cytotoxic killer T cells, critical in cancer therapy.

In addition, Corvus is investigating soquelitinib for other immune-mediated conditions, including atopic dermatitis. The company recently initiated a randomized, double-blind Phase 1 clinical trial to evaluate soquelitinib in patients with moderate to severe atopic dermatitis, aiming to provide an oral treatment alternative to current injectable biologics.

Other promising candidates in Corvus' pipeline include ciforadenant, an adenosine A2A receptor inhibitor that disables tumors' immune evasion mechanisms, and mupadolimab, a monoclonal antibody targeting CD73. These candidates are being studied for their efficacy in combination therapies for various cancers, including head and neck cancers and non-small cell lung cancer.

Financially, Corvus maintains a strong position, having raised significant capital through direct offerings to support its clinical trials and operational needs. With cash reserves projected to fund operations into late 2025, Corvus is well-positioned to achieve substantial milestones in its clinical programs. The company continues to foster critical partnerships, including collaborations with Angel Pharmaceuticals for the Chinese market.

Latest news highlights Corvus' progress in clinical trials and strategic financing moves, underscoring its commitment to bringing innovative immunotherapies to patients in need. For more information, visit the Corvus Pharmaceuticals website.

Rhea-AI Summary

Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker CRVS, has announced that it will participate in the Jefferies Global Health Conference in New York from June 5-7, 2024. The company's CEO, Richard A. Miller, and Chief Business Officer, Jeffrey Arcara, will present a corporate overview and conduct one-on-one meetings with investors. The presentation is scheduled for June 5 at 3:00 pm ET and will be webcast live, with the recording available for 90 days on the company's investor relations webpage.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.37%
Tags
conferences
-
Rhea-AI Summary

Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company, reported strong progress in advancing soquelitinib for PTCL and generating early data for atopic dermatitis. Recent financing provided runway for expected clinical readouts in 2024-2025. Positive Phase 1 trial results for ciforadenant in renal cell cancer. Corvus also collaborates with Kidney Cancer Research Consortium and Angel Pharmaceuticals. Financially, Corvus reported cash, cash equivalents, and marketable securities of $22.1 million as of March 31, 2024, with expected full year 2024 net cash used in operating activities between $24-27 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.04%
Tags
-
Rhea-AI Summary

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) will provide a business update and report first quarter 2024 financial results on May 6, 2024. The company will host a conference call and webcast at 4:30 pm ET / 1:30 pm PT. Investors can access the call through dial-in numbers or the webcast link. A replay will be available on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.98%
Tags
Rhea-AI Summary

Corvus Pharmaceuticals has announced a $30.6 million registered direct offering to raise gross proceeds through the sale of common stock and warrants. The offering includes participation from various healthcare investors and existing investors, with the company's CEO also joining. The offering is expected to close on May 6, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.45%
Tags
-
Rhea-AI Summary
Corvus Pharmaceuticals announces the initiation of a Phase 1 clinical trial for soquelitinib in patients with atopic dermatitis, with potential initial clinical data before year-end 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.36%
Tags
-
Rhea-AI Summary
Corvus Pharmaceuticals, Inc. (CRVS) provides a business update, highlighting progress with soquelitinib in Phase 3 clinical trial for PTCL and Phase 1 trial for atopic dermatitis. Positive interim data from Phase 1/1b trial, Orphan Drug Designation, and FDA alignment for Phase 3 trial are key milestones. The company plans to initiate trials in 2024. Financially, Corvus had $27.1 million in cash as of December 31, 2023, with a net loss of $6.7 million for Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.61%
Tags
Rhea-AI Summary
Corvus Pharmaceuticals, Inc. (CRVS) will host a conference call and webcast on March 19, 2024, to discuss business updates and report financial results for Q4 and full year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6%
Tags
-
Rhea-AI Summary
Corvus Pharmaceuticals, Inc. unveils next-gen ITK inhibitor candidates for precise T cell modulation in immunology indications. Preclinical data for soquelitinib program presented at Keystone Symposia. Next-gen candidates aim to enable more precise inhibition of Th1, Th2, and Th17 cell function. Various disease types targeted with refined chemical structures. Soquelitinib shows activity in six T cell-mediated inflammatory and immune diseases. Potential to treat atopic dermatitis, asthma, psoriasis, rheumatoid arthritis, and more.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.48%
Tags
-
Rhea-AI Summary
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) has received Orphan Drug Designation from the FDA for its lead ITK inhibitor candidate, soquelitinib, for the treatment of T cell lymphoma. The company is set to initiate a Phase 3 registrational clinical trial for soquelitinib in patients with relapsed peripheral T cell lymphoma in the second quarter of 2024. The orphan drug status provides various benefits to the drug developer, including tax credits, exemptions from certain FDA fees, and seven years of post-approval marketing exclusivity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.75%
Tags
Rhea-AI Summary
Corvus Pharmaceuticals, Inc. (CRVS) appoints Jeffrey Arcara as Chief Business Officer, bringing over 30 years of experience in the biopharmaceutical industry. Arcara will lead corporate strategy, business development, and new product planning, strengthening Corvus' ITK programs. His extensive industry experience includes roles at Teva Pharmaceuticals, Neuromed, Wyeth, and InKine Pharmaceutical Company. Arcara holds an MBA from UCLA and a B.A. in Finance and Marketing from University of Wisconsin-Madison.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
management

FAQ

What is Corvus Pharmaceuticals' lead product candidate?

Corvus Pharmaceuticals' lead product candidate is soquelitinib (formerly CPI-818), an investigational small molecule drug designed to selectively inhibit ITK (interleukin-2-inducible T cell kinase).

What conditions is Corvus Pharmaceuticals targeting with soquelitinib?

Soquelitinib is being developed for the treatment of relapsed peripheral T cell lymphoma (PTCL), atopic dermatitis, and potentially other autoimmune and cancer indications.

What is the significance of ITK inhibition in Corvus Pharmaceuticals' research?

ITK inhibition plays a key role in optimizing T cell differentiation and enhancing immune responses, which can be critical for treating cancers and immune diseases.

What other products are in Corvus Pharmaceuticals' pipeline?

Corvus' pipeline includes ciforadenant (an adenosine A2A receptor inhibitor) and mupadolimab (a monoclonal antibody targeting CD73), both of which are being evaluated in combination therapies for various cancers.

What recent financial developments have supported Corvus Pharmaceuticals' research?

Corvus recently raised approximately $30.6 million through a registered direct offering, bolstering its cash reserves to fund ongoing and upcoming clinical trials.

What is the background of Corvus Pharmaceuticals?

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in novel immunotherapies. It was co-founded by Richard A. Miller, M.D., who also serves as its president and CEO.

What partnerships does Corvus Pharmaceuticals have?

Corvus Pharmaceuticals collaborates with Angel Pharmaceuticals to develop and commercialize its leading candidates in China and has invested heavily in top-tier scientific talent and innovative research.

How is Corvus Pharmaceuticals addressing the unmet needs in relapsed PTCL?

Corvus is advancing soquelitinib through a Phase 3 registrational trial for relapsed PTCL, aiming to provide a new therapy for a condition with limited existing treatment options.

How is soquelitinib being evaluated for atopic dermatitis?

A Phase 1 clinical trial for soquelitinib in patients with moderate to severe atopic dermatitis has been initiated to evaluate its safety, tolerability, and efficacy.

What makes mupadolimab unique in Corvus Pharmaceuticals' research?

Mupadolimab is designed to target CD73, stimulating B cells and blocking immunosuppressive adenosine production, enhancing the immune response in cancer treatments.

Corvus Pharmaceuticals, Inc.

Nasdaq:CRVS

CRVS Rankings

CRVS Stock Data

127.60M
34.40M
3.89%
39.96%
2.85%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BURLINGAME